Case Report on Dedifferentiated Carcinoma of Endometrium and It’s Histopathological Characteristics

The DEAC, a rare entity, has an unfavorable clinical outcome. The role of adjuvant therapy is also controversial in this high-risk variety. The current FIGO grading may also lead to misdiagnosis of DEAC as FIGO grade 2 or 3 endometroid carcinoma, owing to histological insufficiency in assessing the details of solid component within a tumor. The recognition of UC component as a solid patternless growth is extremely important for a correct diagnosis of DEAC. Hereby, a 51-year-old female is presented with chief complaint of postmenopausal bleeding, with D&C report of a poorly differentiated carcinoma of endometrium. Complete comprehensive surgical staging was performed. The final HPE revealed 85–90% UC and 10–15% moderately differentiated endometroid carcinoma, which was finally IHC-proven as well. The disease was found metastatic to adnexa and retroperitoneal lymph nodes. Postoperatively patient was given chemotherapy as adjuvant therapy and she is asymptomatic on follow-up.